In addition, it has been reported that O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, which has been regarded as the indicator of temozolomide (TMZ) chemotherapy resistance, is also more likely to occur in glioma female patients (14). The gene discussed is MGMT; the disease is central nervous system cancer.